Actuate Therapeutics Inc. (ACTU) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Actuate Therapeutics Inc. (NASDAQ: ACTU) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $0.34 (-9.68% 1D, market cap $18.4M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ACTU ranks #610 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ACTU carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, KYNB (Kyntra Bio Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $18.5M) and AKTX (Akari Therapeutics plc ADS) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $18.8M). Among the 5-stock peer group, ACTU leads on earnings multiple (N/A) while ACTU leads on capital efficiency (-35.0% ROIC).
Per ACTU's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001652935), Actuate Therapeutics Inc. generated $0 in revenue, -$22.2M in net income, and -$19.2M in free cash flow against $14.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 33.3 (NEUTRAL RANGE)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While ACTU currently carries a cautious 35/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.87) and Max Pain ($0.36) forces dealer call-delta covering toward $8.29.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Actuate Therapeutics Inc. (ACTU) dropped -9.68% to $0.34, trading at 2% of its 52-week range ($0.33 – $7.9). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo! Finance Canada report covering Actuate Therapeutics Inc. (ACTU) market action, institutional positioning, and fundamental catalysts.
Moomoo report covering Actuate Therapeutics Inc. (ACTU) market action, institutional positioning, and fundamental catalysts.
Quantisnow report covering Actuate Therapeutics Inc. (ACTU) market action, institutional positioning, and fundamental catalysts.
WBOC TV report covering Actuate Therapeutics Inc. (ACTU) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Actuate Therapeutics Inc. (ACTU) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Actuate Therapeutics Inc. (ACTU) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Actuate Therapeutics Inc. (ACTU) market action, institutional positioning, and fundamental catalysts.
GuruFocus report covering Actuate Therapeutics Inc. (ACTU) market action, institutional positioning, and fundamental catalysts.
Premarket movers for Nov. 2, 2026: CLRO and EVGO led gainers while KPTI and DRUG led decliners ahead of the US open.
Oral tablet form expected to allow Company to optimize patient plasma exposure levels with convenient daily dosing of drug Sustained plasma levels of elraglusib expected to have multiple effects on immune cell dynamics w
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ACTU today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ACTU. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Actuate Therapeutics Inc. (ACTU) ranks #610 by composite RQD confidence (35/100, grade D-) and #836 by equity capitalization ($18.4M). Within this direct 5-issuer industry benchmark cohort, ACTU leads on earnings valuation at N/A trailing P/E, while ACTU leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. MCRB currently holds the highest overall quantitative score in the immediate peer group at 40/100 (D-) compared with ACTU at 35/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ACTU
ACTIVE
Actuate Therapeutics Inc. | D- | 35/100 | — | — | -35.0% | -9.68% | $18.4M | Benchmark Subject |
| KYNB Kyntra Bio Inc. | E | 32/100 | — | 91.4% | -35.0% | -1.72% | $18.5M | /kynb-vs-actu → |
| AKTX Akari Therapeutics plc ADS | D- | 37/100 | — | — | -35.0% | +3.00% | $18.8M | /aktx-vs-actu → |
| MCRB Seres Therapeutics Inc. | D- | 40/100 | — | — | -35.0% | -9.23% | $17.8M | /mcrb-vs-actu → |
| COCP Cocrystal Pharma Inc. | D- | 36/100 | — | — | -35.0% | +1.53% | $19.2M | /cocp-vs-actu → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Actuate Therapeutics Inc. (ACTU) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$22.2M, operating cash flow of -$19.2M, and free cash flow of -$19.2M (+12.1% YoY). On the balance sheet, ACTU closed FY2025 with $14.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$22.2M | -$19.2M | -$19.2M | $14.0M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$27.3M | -$21.8M | -$21.8M | $9.3M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$24.7M | -$21.6M | -$21.6M | — | — |
As of 2026-11-03, Actuate Therapeutics Inc. (NASDAQ: ACTU) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $0.34 (-9.68% 1D, market cap $18.4M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ACTU ranks #610 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ACTU carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, KYNB (Kyntra Bio Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $18.5M) and AKTX (Akari Therapeutics plc ADS) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $18.8M). Among the 5-stock peer group, ACTU leads on earnings multiple (N/A) while ACTU leads on capital efficiency (-35.0% ROIC).
Per ACTU's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001652935), Actuate Therapeutics Inc. generated $0 in revenue, -$22.2M in net income, and -$19.2M in free cash flow against $14.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
ACTU last traded at $0.34 (-9.68% on volume of 489,506 shares), positioning the stock -60.92% below its 50-day simple moving average ($0.87) and -83.89% below its 200-day simple moving average ($2.11). Across its 52-week range of $0.33 to $7.90, ACTU sits at the 0.1% percentile with a 14-day RSI of 33.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.38).
Why ACTU Stock dropped -9.68% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, ACTU scores 35 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:
Taken together, the pillar scores point to weak cash generation and a balance sheet that the rating treats as vulnerable. A prospective investor evaluating the stock today would weigh the sharp price decline (52-week range $0.33 to $7.9) against the ongoing cash burn reflected in the financials. Upside would depend on the company converting its financing activity into sustained operating progress, which the source data does not demonstrate. Valuation cannot be assessed on earnings multiples because P/E and EV/EBITDA are unavailable in the source data.
Actuate Therapeutics Inc. is a NASDAQ-listed issuer classified under the Health Care sector and the Biotechnology: Pharmaceutical Preparations industry, per the profile. The source data does not describe specific products, customers, or revenue streams. The FY 2025 and FY 2024 revenue figures are reported as $0.0M, and the company's model of monetization is not detailed in the sources.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-22.5M | $-22.2M | N/A | $-19.2M | $13.2M | N/A |
| FY 2024 | $0.0M | $-25.2M | $-27.3M | N/A | $-21.8M | $8.6M | N/A |
| FY 2023 | $0.0M | $-25.0M | $-24.7M | N/A | $-21.6M | N/A | N/A |
Per the SEC financials, the company reported no revenue across the three periods and operating losses in each year. Net margin, gross margin, and operating margin are each listed as 0% in the market data, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 3/9, with a Debt/Equity ratio of 0.5. Cash rose from $8.6M in FY 2024 to $13.2M in FY 2025 while free cash flow remained negative, and the source data does not reconcile how that cash increase was funded.
The news feed contains six items, all tagged to ACTU:
The most material items are the financing announcements. Per the news wire, the company priced an $11.0 Million underwritten public offering and separately raised $9.96 Million through a stock-and-warrant offering. These financings are consistent with the cash figure of $13.2M in FY 2025 and the continued negative free cash flow. The Butterfly supply-chain graph reports no proprietary signals, so there are no additional signal-based catalysts in the source data. The risk watch item is dilution: the offering price referenced as assumed at $0.819 per share compares with the current price of 0.37 in the market data.
Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies cannot be identified from the source data. Sector correlations are likewise not available beyond the classification of Health Care and Biotechnology: Pharmaceutical Preparations. A prospective investor should note that the absence of mapped links means second-order bottlenecks cannot be assessed here, and any ripple analysis would require information outside this source set.
Real-time company headlines, analyst actions, and sector developments for Actuate Therapeutics Inc. (ACTU) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo! Finance Canada report covering Actuate Therapeutics Inc. (ACTU) market action, institutional positioning, and fundamental catalysts.
Moomoo report covering Actuate Therapeutics Inc. (ACTU) market action, institutional positioning, and fundamental catalysts.
Quantisnow report covering Actuate Therapeutics Inc. (ACTU) market action, institutional positioning, and fundamental catalysts.
WBOC TV report covering Actuate Therapeutics Inc. (ACTU) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Actuate Therapeutics Inc. (ACTU) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Actuate Therapeutics Inc. (ACTU) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Actuate Therapeutics Inc. (ACTU) market action, institutional positioning, and fundamental catalysts.
GuruFocus report covering Actuate Therapeutics Inc. (ACTU) market action, institutional positioning, and fundamental catalysts.
Welcome to the ACTU (Actuate Therapeutics Inc.) Roar Pit. Current RQD Composite is 35/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on ACTU, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Actuate Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on ACTU, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $0.37 (52-wk range $0.33 - $7.90), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).